DOCSLIB.ORG

Jefferies 2013 Global Healthcare Conference in London

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jefferies 2013 Global Healthcare Conference in London Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc. Array BioPharma, Inc. Polpharma S.A. Biotechnology Pharmaceuticals Biotechnology Pharmaceuticals Reinhard Kandera, CFO Alex Kudrin, Vice President, Product Ron Squarer, CEO Piotr Hrycaj; M&A Director Development Division 9:20 AM Seattle Genetics Inc. Mallinckrodt H. Lundbeck A/S Hyperion Therapeutics, Inc. Biotechnology Pharmaceuticals Pharmaceuticals Biotechnology Clay Siegall; President and CEO Mark Trudeau; CEO & Matthew Harbaugh, Anders Göetzsche; CFO Donald Santel; CEO Senior VP and CFO 10:00 AM IMS Healthcare Incorporated Synageva BioPharma Corp Farmak JSC Optos PLC Healthcare Services Biotechnology Pharmaceuticals Medical Technology Stefan Linn; SVP Global Pharma Sang Patel; President & CEO Filya Zhebrovska; Chairman and CEO Roy Davis; CEO 10:40 AM Dechra Pharmaceuticals Novo Nordisk A/S Alere Inc. Cosmo Pharmaceuticals SpA Pharmaceuticals Pharmaceuticals Biotechnology Biotechnology Ian Page; CEO & Anne-Francoise Nesmes, CFO Lars Borup Jacobsen; Manager of IR Jon Russell; Vice President Finance Chris Tanner; CFO and Head of IR 11:20 AM Amplifon SpA Lonza Group AG Swedish Orphan Biovitrum AB AMCo Healthcare Services Biotechnology Biotechnology Pharmaceuticals Ugo Giorcelli; CFO Toralf Haag; CFO Geoffrey McDonough; CEO John Beighton; CEO 12:00 PM Break – Working Lunch Presenting companies and speakers are subject to change. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 12:20 PM Consort Medical Plc Kadmon Corporation Panel – Changing Pharma Business Models Martindale Pharmaceuticals Ltd. Medical Technology Biotechnology Mark Trudeau, CEO, Mallinckrodt Pharmaceuticals Jonathan Glenn; CEO Samuel Waksal; Chairman & CEO Peter Stein, CEO, Norgine Richard de Souza; CEO Hakan Bjorklund, former CEO, Nycomed Vassilios Katsos, CEO, Pharmathen Dr. Michael Mehler, CEO, Riemser 1:00 PM Galenica Ltd. Orpea S.A. Novozymes A/S Cempra, Inc. Pharmaceuticals Healthcare Services Pharmaceuticals Pharmaceuticals Fritz Hirsbrunner; Head of IR Steve Grobet; IR Dave Mead, Business Development Director Prabhavathi Fernandes; President and CEO 1:40 PM Al Noor Hospitals Group Plc PAREXEL International Corporation Lexicon Pharmaceuticals, Inc. Norgine Healthcare Services Healthcare Services Biotechnology Pharmaceuticals Sami Alom; Chief Strategy Officer & Director, IR James Winschel; Jeff Wade; CFO & Brian Zambrowicz, EVP and Peter Stein; CEO Executive Vice President and CFO CSO 2:20 PM BTG Plc Medivation, Inc. ALK-Abello Cell Therapeutics Inc. Biotechnology Biotechnology Pharmaceuticals Biotechnology Louise Makin; CEO David Hung (MD); President & CEO Jens Bager; President and CEO James Bianco; President and CEO 3:00 PM Vectura Group Plc Medical Properties Trust Galapagos NV Alvogen Group Pharmaceuticals Healthcare Services Biotechnology Pharmaceuticals Christopher Blackwell; CEO Edward K. Alda-George, Jr.; Chairman, President Guillaume Jetten; CFO Kevin Bain; CFO & CEO and Richard S. Hamner, EVP and CFO 3:40 PM Enzymotec, Ltd. Ipsen S.A. NMC Health Plc Epizyme, Inc. Biotechnology Pharmaceuticals Healthcare Services Biotechnology Ariel Katz, CEO Susheel Surpal; EVP Finance & CFO & Roy Cherry; Head of Strategy and IR Jason Rhodes; CFO Claude Bertand CSO 4:20 PM ThromboGenics NV Bavarian Nordic A/S Gerresheimer AG Biocon Ltd. (Syngene International) Biotechnology Biotechnology Medical Technology Healthcare Services Patrick De Haes, CEO Anders Hedegaard; President and CEO Anke Linnartz; Director IR Peter Bains; Director 5:00 PM Zealand Pharma A/S NewLink Genetics Corporation Osmotica Pharmaceutical Esteve Biotechnology Biotechnology Pharmaceuticals Pharmaceuticals David Solomon; President and CEO Gordon Link; CFO Praveen Tyle; President and CEO Mark Mayhew; Head of Strategic Development for Pharma Presenting companies and speakers are subject to change. AGENDA THURSDAY, 21 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM GW Pharmaceuticals Transgene SA Biotest AG AMAG Pharmaceuticals, Inc. Pharmaceuticals Biotechnology Biotechnology Biotechnology Justin Gover; CEO Stephane Boissel, CFO Professor Dr. Gregor Schulz; CEO & Michael Frank Thomas, COO Ramroth, CFO 8:40 AM Intercept Pharmaceuticals, Inc. Varian Medical Systems Inc. NPS Pharmaceuticals Inc. Helsinn Healthcare SA Pharmaceuticals Medical Technology Biotechnology Pharmaceuticals Barbara Duncan; CFO Neil Madle; Director, IR Francois Nader; President and CEO Roberto De Ponti; Head of Corporate BD 9:20 AM Cipla Ltd. Pacira Pharmaceuticals Inc. BioMarin Pharmaceutical Inc. Valenta Pharmaceuticals JSC Pharmaceuticals Pharmaceuticals Biotechnology Pharmaceuticals Subhanu Saxena; CEO & Rajesh Garg CFO Dave Stack; President & CEO Jean-Jacques Bienaime; CEO Sergei Zaiats; Director of Strategic Products 10:00 AM Aratana Therapeutics, Inc. Covidien plc Aegerion Pharmaceuticals, Inc. Antares Pharma Inc. Pharmaceuticals Medical Technology Biotechnology Pharmaceuticals Steven St. Peter, President and CEO Cole Lannum, VP of Investor Relations Mark Fitzpatrick; CFO Paul Wotton; President and CEO 10:40 AM Smith & Nephew plc AbbVie Inc. PDL BioPharma, Inc. Putney, Inc. Medical Technology Pharmaceuticals Biotechnology Pharmaceuticals Julie Brown; CFO Scott Brun; Vice President, John P. McLaughlin; President and CEO Jean Hoffman; President & CEO Pharmaceutical Development 11:20 AM Actelion Ltd. Novartis AG Henry Schein, Inc. Ethypharm SA Biotechnology Pharmaceuticals Healthcare Services Pharmaceuticals Otto Schwarz; COO Harry Kirsch; CFO Ferdinand Jahnel, Vice President, Treasurer Hugues Lecat; CEO and Chairman 12:00 PM Break – Working Lunch Presenting companies and speakers are subject to change. AGENDA THURSDAY, 21 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 12:20 PM Ambu A/S Targacept, Inc. Panel – Biosimilar Antibodies Orexo AB Medical Technology Biotechnology 1. Michael Kotsanis, COO, Synthon Biotechnology Lars Marcher; President and CEO Dr. Stephen A. Hill; President and CEO 2. Raymond de Vrie – SVP, Commercial Biologics, Nikolaj Sorensen; CEO Dr. Reddy's 3. Dr. Udo Hartlaub – Head of Global Regulatory Affairs Biosimilars,Teva 4. Richard DiCicco – Chairman, Harvest Moon Pharmaceuticals 5. Marwood Group 6. IMS 1:00 PM UDG Healthcare Plc Arseus NV Morphosys AG Durata Therapeutics Healthcare Services Healthcare Services Biotechnology Pharmaceuticals Liam Fitzgerald, CEO Ger van Jeveren; CEO Jens Holstein; CFO Paul Edick; CEO 1:40 PM Recordati SpA ImmunoGen, Inc. Genmab AS Pharmathen S.A. Pharmaceuticals Biotechnology Biotechnology Pharmaceuticals Fritz Squindo, CFO Charles Morris; EVP and Jan van de Winkel; President and CEO Vassilios Katsos; President and CEO Chief Development Officer 2:20 PM Eurofins Scientific SA Gulf Pharmaceuticals Industries (Julphar) Haemonetics Corp Zeltia SA Medical Technology Pharmaceuticals Medical Technology Biotechnology Dr. Gilles Martin, Chairman and CEO GVG Krishna, CFO Christopher Lindop, CFO & Michael Kelly; Dr. José María Fernandez; President, Global Markets Chairman group Zeltia 3:00 PM GN Store Nord A/S Sanofi Verastem Symetis SA Medical Technology Pharmaceuticals Pharmaceuticals Medical Technology Lars Viksmoen, CEO Sebastien Martel; VP & Head of IR Robert Forrester; President & CEO Jacques Essinger; CEO 3:40 PM Stratec Biomedical AG Kamada Ltd. Sartorius AG Synthon Holdings B.V. Biotechnology Biotechnology Medical Technology Pharmaceuticals Marcus Wolfinger; Chairman, Gil Efron, CFO & Pnina Strauss, Vice President Joerg Pfirrmann; CFO Michael Kotsanis; CCO Board of Management
Load more

Recommended publications
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Cboe UK Healthcare Sector Index BUKHLTH
    Cboe UK Healthcare Sector Index BUKHLTH Page 1 August 2021 Cboe Exchange This sector represents products and services that are designed, developed, and utilized in the promotion of health and well-being, including medical services, health plans, medical devices, and biopharmaceuticals. The parent index is the Cboe UK All Companies (BUKAC). The index base level is 10,000 as of December 31st, 2010. This is a price return index. Objective The index is designed for use in the creation of index tracking funds, derivatives and as a performance benchmark. Investability Liquidity Transparency Availability Stocks are selected and Stocks are screened to Uses a transparent, rules-based Calculation is based on weighted to ensure that the ensure that the index is construction process. Index price and total return index is investable. tradable. Rules are freely available on the methodologies, both real cboe.com/europe/indices -time, intra-second and website. end of day. Statistics Index ISIN Ticker RIC Currency Cboe UK Healthcare Sector DE000SLA1DJ6 BUKHLTH .BUKHLTH GBP Cboe UK Healthcare Sector - net DE000SLA18F5 BUKHLTHN .BUKHLTHN GBP Volatility Volatility (1y) 0.1776 Returns(%) 1M 3M 6M YTD 1Y 3Y 5Y BUKHLTH 2.03 2.35 16.31 7.02 -2.85 13.78 17.14 BUKHLTHN 2.97 3.33 18.35 10.28 0.52 26.24 39.74 Top 5 Performers Country 1 month return % INDIVIOR PLC UNITED KINGDOM 17.70 MEDICLINIC INTERNATIONAL PLC UNITED KINGDOM 12.80 OXFORD BIOMEDICA PLC UNITED KINGDOM 11.38 PURETECH HEALTH PLC UNITED KINGDOM 8.77 VECTURA GROUP PLC UNITED KINGDOM 7.76 Historical Performance Chart 100% 80% 60% 40% 20% 0% 2011 2013 2014 2016 2017 2018 2020 2021 Cboe UK Healthcare Sector (GBP) Cboe UK All Companies (GBP) Cboe.com | ©Cboe | /CboeGlobalMarkets | /company/cboe © 2021 Cboe Exchange, Inc.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • Portfolio Holdings Listing Fidelity International Small Cap Opportunities Fund DUMMY As of June 30, 2021
    Portfolio Holdings Listing Fidelity International Small Cap Opportunities Fund DUMMY as of June 30, 2021 The portfolio holdings listing (listing) provides information on a fund’s investments as of the date indicated. Top 10 holdings information (top 10 holdings) is also provided for certain equity and high income funds. The listing and top 10 holdings are not part of a fund’s annual/semiannual report or Form N-Q and have not been audited. The information provided in this listing and top 10 holdings may differ from a fund’s holdings disclosed in its annual/semiannual report and Form N-Q as follows, where applicable: With certain exceptions, the listing and top 10 holdings provide information on the direct holdings of a fund as well as a fund’s pro rata share of any securities and other investments held indirectly through investment in underlying non- money market Fidelity Central Funds. A fund’s pro rata share of the underlying holdings of any investment in high income and floating rate central funds is provided at a fund’s fiscal quarter end. For certain funds, direct holdings in high income or convertible securities are presented at a fund’s fiscal quarter end and are presented collectively for other periods. For the annual/semiannual report, a fund’s investments include trades executed through the end of the last business day of the period. This listing and the top 10 holdings include trades executed through the end of the prior business day. The listing includes any investment in derivative instruments, and excludes the value of any cash collateral held for securities on loan and a fund’s net other assets.
    [Show full text]
  • 20 Years of Strategic Growth
    Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2017 20 Years of Strategic Growth ® Stock Code: DPH Annual Report and Accounts for the year ended 30 June 2017 Company Number: 3369634 slugline Dechra Annual Report 2017 - Front.indd 3 slugline 9/14/2017 8:32:51 AM Welcome to Dechra Pharmaceuticals PLC Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Getting Around the Report Forward-Looking Statements Icons are used within the Report to assist the reader to identify This document contains certain forward-looking statements. links to other relevant sections of interest. Below is a selection The forward-looking statements reflect the knowledge and of icons you will see used within this Report: information available to the Company during preparation and up to the publication of this document. By their very nature, For more information see further pages these statements depend upon circumstances and relate to within the Report events that may occur in the future and thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company. More information online at: www.dechra.com Glossary Terms used within this section Open the flaps to view Our History Dechra Annual Report 2017 - Front.indd 4 slugline 04/09/2017 13:58:27 Delivering Consistently for Our Shareholders Dechra is a company that has consistently delivered on its strategic objectives resulting in a strong track record of growth.
    [Show full text]
  • FTSE Publications
    2 FTSE Russell Publications FTSE Developed Europe SMID Cap 19 August 2021 Tradable Plus Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Group 0.72 UNITED Bureau Veritas S.A. 0.42 FRANCE Gjensidige Forsikring ASA 0.17 NORWAY KINGDOM Campari 0.31 ITALY Gn Store Nordic 0.53 DENMARK AAK 0.18 SWEDEN Carl Zeiss Meditec 0.33 GERMANY Halma 0.66 UNITED Aalberts NV 0.24 NETHERLANDS Castellum 0.32 SWEDEN KINGDOM ABN AMRO Bank NV 0.23 NETHERLANDS Centrica 0.2 UNITED Hargreaves Lansdown 0.39 UNITED Acciona S.A. 0.16 SPAIN KINGDOM KINGDOM Accor 0.32 FRANCE Chr. Hansen Holding A/S 0.43 DENMARK Hays 0.16 UNITED ACS Actividades Cons y Serv 0.3 SPAIN Clariant 0.21 SWITZERLAND KINGDOM Adecco Group AG 0.49 SWITZERLAND Coca-Cola HBC AG 0.33 UNITED HeidelbergCement AG 0.6 GERMANY Adevinta 0.21 NORWAY KINGDOM HelloFresh SE 0.67 GERMANY Admiral Group 0.43 UNITED Cofinimmo 0.21 BELGIUM Helvetia Holding AG 0.18 SWITZERLAND KINGDOM Commerzbank 0.35 GERMANY Hikma Pharmaceuticals 0.27 UNITED Aedifica 0.22 BELGIUM ConvaTec Group 0.25 UNITED KINGDOM Aegon NV 0.34 NETHERLANDS KINGDOM Hiscox 0.18 UNITED KINGDOM Aeroports de Paris 0.17 FRANCE Countryside Properties 0.16 UNITED Holmen AB 0.2 SWEDEN Ageas 0.46 BELGIUM KINGDOM Homeserve 0.17 UNITED Aker BP ASA 0.16 NORWAY Covestro AG 0.54 GERMANY KINGDOM Alfa Laval 0.52 SWEDEN Covivio 0.2 FRANCE Howden Joinery Group 0.3 UNITED Alstom 0.7 FRANCE Croda International 0.64 UNITED KINGDOM KINGDOM Alten 0.18
    [Show full text]
  • RCP BIA 2020 Review January 2021 FINAL.Pdf
    UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Brown Capital Management International Small Company Fund Schedule of Investments As of December 31, 2020 (Unaudited)
    7 Brown Capital Management International Small Company Fund Schedule of Investments As of December 31, 2020 (Unaudited) Shares Value (Note 1) COMMON STOCKS - 96.60% Australia - 6.06% 708,305 REA Group, Ltd. $ 81,287,705 1,464,269 WiseTech Global, Ltd. 34,713,030 116,000,735 Austria - 0.72% 364,651 Schoeller-Bleckmann Oilfield Equipment AG 13,854,217 Canada - 8.81% (a) 1,493,328 Descartes Systems Group, Inc. 87,342,501 (a) 574,515 Kinaxis, Inc. 81,395,267 168,737,768 Denmark - 8.36% 1,718,159 Ambu A/S - Class B 74,226,815 1,231,585 NNIT A/S 24,581,567 412,166 SimCorp A/S 61,259,325 160,067,707 France - 10.09% 1,499,660 Albioma SA 86,106,283 12,180 Esker SA 2,627,739 1,167,698 Interparfums SA 61,268,589 1,412,713 Lectra 43,145,760 193,148,371 Germany - 13.03% (a) 2,470,144 Evotec SE 91,373,934 1,216,343 Nexus AG 75,782,759 548,366 STRATEC SE 82,264,614 249,421,307 Hong Kong - 3.55% 16,666,000 Kingdee International Software Group Co., Ltd. 67,932,795 India - 1.37% 588,229 CRISIL, Ltd. 15,469,415 1,862,265 Emami, Ltd. 10,800,079 26,269,494 Ireland - 1.34% 125,371 Flutter Entertainment PLC 25,562,163 Israel - 3.46% (a) 410,426 CyberArk Software, Ltd. 66,320,737 Italy - 1.62% 1,424,162 Azimut Holding SpA 30,916,548 Japan - 12.95% 245,400 GMO Payment Gateway, Inc.
    [Show full text]
  • Oxford Biomedica Delivering Commercial Gene-Therapy Vector
    31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles.
    [Show full text]
  • Coleman Street Investments
    1 | COLEMAN STREET INVESTMENTS COLEMAN STREET INVESTMENTS A Luxembourg domiciled Open-Ended Investment Fund With multiple sub-funds Annual Report Including audited Financial Statements st As of 31 December, 2018 Luxembourg Corporate and Trade Register RCS No B175-811 No subscriptions can be made on the basis of this annual report including audited annual financial statements. Subscriptions are only valid if they are made on the basis of the latest prospectus accompanied by the last Annual Report including Audited Financial Statements and the last unaudited semi-annual Report, if the latter is more recent than the Annual Report including audited financial statements. The subscription, conversion and repurchasing forms can be obtained on request addressed to the Registered Office of the Company at 287, Route d’Arlon, L-1150 Luxembourg, G.D.L. 2 | COLEMAN STREET INVESTMENTS TABLE OF CONTENTS ORGANISATION AND ADMINISTRATION ................................................................................................................................................. 3 MANAGEMENT REPORT ........................................................................................................................................................................... 6 REPORT OF THE REVISEUR D’ENTREPRISES AGREE .......................................................................................................................... 9 STATEMENT OF NET ASSETS ...............................................................................................................................................................
    [Show full text]
  • Misinterpretation of Time-To-First Event Curves Can Lead to Inappropriate Treatment
    AGORA | CORRESPONDENCE Misinterpretation of time-to-first event curves can lead to inappropriate treatment To the Editor: Great care should be taken when assessing the consistency of treatment effect over time based on a survival curve plot, and even more so when a treatment affects a repeating event end-point, such as exacerbations, rather than an event that can occur only once, like death. In their recent editorial in the European Respiratory Journal,SUISSA and ARIEL [1] make the assertation that survival functions plotted from Kaplan–Meier estimates from figure 1b in the IMPACT study [2] “clearly show that the difference in the rate of exacerbation between LAMA/LABA/ICS and LAMA/LABA over follow-up is due to the first month’s surge, with practically no differences in the subsequent rates between the two groups”. However, this statement is based on a misunderstanding of the survival analyses presented. The events plotted on the figure are the first moderate or severe COPD exacerbations experienced by a patient in the IMPACT study. The statements made by SUISSA and ARIEL [1] about exacerbation rates refer to the rate of first exacerbations only, and not to the rate of all exacerbations during the study. Their conclusion that the rates of first exacerbations, and ratio between those rates changes over time is correct. However, this is entirely in line with statistical theory for repeated events with overall constant rates. It cannot be used to support any conclusion that the difference in the rate of exacerbation is due to a “first month’s surge”. The “digitised” curve of first events behaves entirely consistently with constant rate events.
    [Show full text]